Oxcarbazepine

Indication

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Amber level 0

Brand:

Trileptal®

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Central nervous system

Background

Oxcarbazepine (Trileptal®) is recommended for use as monotherapy or adjunctive therapy in partial (focal) epilepsy only when carbamazepine, lamotrigine, sodium valproate and levetiracetam are not appropriate or not tolerated.

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

OXCARBAZEPINE LMMG New Medicine Review

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Pending	Amber 0	Amber 0	Pending	Amber 0	Amber 0	Amber 0	Amber 0

What do the colours mean?

Last Updated: 01 - Sep - 2013